Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219997 | 0.84 | CYP19A1 (0.45) | CYP2A6ALDH1A1KDM4EL3MBTL1HPGD | |
| SCHEMBL17845779 | 0.83 | KDM4E (0.42) | CYP2A6ALDH1A1KDM4EL3MBTL1HPGD | |
| SCHEMBL7213728 | 0.81 | KDM4E (0.49) | CYP2A6ALDH1A1KDM4EL3MBTL1HPGD | |
| SCHEMBL6263230 | 0.80 | LOXL2 (0.52) | CYP2A6ALDH1A1KDM4EL3MBTL1HPGD | |
| SCHEMBL1042523 | 0.80 | KDM4E (0.40) | ALDH1A1KDM4EL3MBTL1HPGDHTT | |
| SCHEMBL23019527 | 0.80 | KDM4E (0.51) | CYP2A6ALDH1A1KDM4EL3MBTL1HPGD | |
| SCHEMBL30832037 | 0.80 | MBOAT4 (0.43) | CYP2A6ALDH1A1KDM4EL3MBTL1HPGD | |
| SCHEMBL507552 | 0.79 | KDM4E (0.42) | CYP2A6ALDH1A1KDM4EL3MBTL1HPGD | |
| SCHEMBL453493 | 0.79 | KDM4E (0.42) | CYP2A6ALDH1A1KDM4EL3MBTL1HPGD | |
| SCHEMBL23171396 | 0.79 | MEN1 (0.43) | CYP2A6ALDH1A1KDM4EL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-05 | — | — | US | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230250129-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022115381-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS CROSS REFERENCE TO RELATED APPLICATION | SAGE THERAPEUTICS, ONC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-11224224-B2 | Thiobenzoimidazole as fungicides | REDAG CROP PROTECTION LTD. (GB) | 2022-01-18 | — | — | US | disclosed |
| WO-2021262836-A1 | 3.ALPHA.-HYDROXY, 17.BETA.-C(O)-N-ARYL SUBSTITUTED NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021096304-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2021-05-20 | — | — | WO | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1697370-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1458392-A4 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1458392-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-6603007-B1 | Intermediates in the fields of pharmaceuticals, agrichemicals, ligands, silver halide photosensitive materials, liquid crystals, surfactants, electrophotography and organic electroluminescence | SANKIO CHEMICAL CO., LTD. (JP) | 2003-08-05 | — | — | US | disclosed |
| WO-2003059269-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-1231207-A1 | NOVEL BIPYRIDYL DERIVATIVES | Sankio Chemical Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | IMPDH2, IMPDH1, XDH | CYP2A6 220/4885ALDH1A1 39/4885KDM4E 2516/4885 |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | CYP2A6 10/4885ALDH1A1 111/4885KDM4E 1884/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CYP2A6 4638/4885ALDH1A1 4701/4885KDM4E 4128/4885 |
| US-11224224-B2 | Thiobenzoimidazole as fungicides | CYP1B1, CYP51A1, CYP1A2 | CYP2A6 68/4885ALDH1A1 280/4885KDM4E 1194/4885 |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | ICMT, INMT, BHMT | CYP2A6 1209/4885ALDH1A1 592/4885KDM4E 2117/4885 |
| US-20230250129-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | MC2R, NR3C2, AVPR1B | CYP2A6 349/4885ALDH1A1 1664/4885KDM4E 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.